title: Doripenem: a review of its use in the treatment of bacterial infections.
abstract: Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults. Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract infections (cUTIs) and a variety of other bacterial infections, such as complicated skin and skin structure infections (cSSSIs), obstetric and gynaecological infections, serious ear, nose and throat infections, sepsis and endocarditis, dental and oral surgical infection, and ophthalmic infection caused by various susceptible strains of Gram-negative, Gram-positive or anaerobic bacteria. Doripenem is indicated in the US for the treatment of complicated IAIs (cIAIs) or cUTIs, including pyelonephritis, caused by susceptible strains of designated pathogens, and in the EU for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia [VAP]), cIAIs or cUTIs.Doripenem has a broad spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, and anaerobic pathogens. The drug also has a low propensity to select for resistance and is suitable for the prolonged infusions that may be required to achieve pharmacodynamic/pharmacokinetic targets for bactericidal activity (and therefore efficacy) against pathogens with increased MICs (minimum concentrations required to inhibit the pathogens). Doripenem is no less effective than other antibacterial agents, including meropenem, imipenem/cilastin, piperacillin/tazobactam or levofloxacin in a wide range of serious bacterial infections, such as complicated lower respiratory infections, nosocomial pneumonia (including VAP), cIAIs and cUTIs, and is well tolerated. Thus, doripenem is a valuable addition to the options available for the empirical treatment of serious bacterial infections in hospitalized patients.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Keam
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015780:Carbapenems / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077726:Doripenem; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem
references.citation: J Infect Chemother. 2002 Dec;8(4):371-3
references.pmid: 12525903
references.citation: Curr Med Res Opin. 2008 Jul;24(7):2113-26
references.pmid: 18549664
references.citation: Drugs. 2003;63(9):913-25; discussion 926
references.pmid: 12678575
references.citation: Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S100-5
references.pmid: 16894511
references.citation: J Infect Chemother. 2005 Oct;11(5):259-61
references.pmid: 16258825
references.citation: J Antimicrob Chemother. 2005 Jun;55(6):965-73
references.pmid: 15849262
references.citation: J Antimicrob Chemother. 2008 Mar;61(3):751-3
references.pmid: 18238882
references.citation: Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91
references.pmid: 16854555
references.citation: Drugs. 2003;63(17):1855-78
references.pmid: 12921489
references.citation: Crit Care Med. 2008 Apr;36(4):1089-96
references.pmid: 18379232
references.citation: Drugs. 2000 Sep;60(3):619-46
references.pmid: 11030471
references.citation: Diagn Microbiol Infect Dis. 2005 May;52(1):71-4
references.pmid: 15878447
references.citation: Chemotherapy. 2000 May-Jun;46(3):184-7
references.pmid: 10765033
references.citation: Drugs. 2007;67(7):1027-52
references.pmid: 17488146
references.citation: Curr Opin Crit Care. 2004 Feb;10(1):59-64
references.pmid: 15166851
references.citation: Drugs. 2003;63(20):2157-68
references.pmid: 14498753
references.citation: Antimicrob Agents Chemother. 2006 Sep;50(9):3150-3
references.pmid: 16940115
references.citation: J Hepatobiliary Pancreat Surg. 2007;14(1):59-67
references.pmid: 17252298
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96
references.pmid: 15047550
references.citation: Antimicrob Agents Chemother. 2004 Aug;48(8):3136-40
references.pmid: 15273134
references.citation: Mol Microbiol. 2005 Apr;56(2):309-22
references.pmid: 15813726
references.citation: Diagn Microbiol Infect Dis. 2006 Jul;55(3):241-3
references.pmid: 16725297
references.citation: Drugs. 1996 Jan;51(1):99-136
references.pmid: 8741235
references.citation: Clin Microbiol Infect. 2007 Jun;13(6):560-78
references.pmid: 17266725
references.citation: Drugs. 2008;68(6):803-38
references.pmid: 18416587
references.citation: Drugs. 2008;68(2):165-89
references.pmid: 18197724
references.citation: In Vivo. 2006 Jan-Feb;20(1):91-6
references.pmid: 16433034
references.citation: Drug Metab Dispos. 2004 Dec;32(12):1383-91
references.pmid: 15345660
references.citation: Toxicology. 2006 May 1;222(1-2):114-24
references.pmid: 16549226
references.citation: Clin Infect Dis. 2003 Oct 15;37(8):997-1005
references.pmid: 14523762
references.citation: Drugs. 2005;65(15):2151-78
references.pmid: 16225376
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1313-9
references.pmid: 15047535
references.citation: Clin Pharmacokinet. 2000 Sep;39(3):185-201
references.pmid: 11020134
references.citation: Antimicrob Agents Chemother. 2001 Apr;45(4):1284-6
references.pmid: 11257048
references.citation: Clin Ther. 2008 May;30(5):868-83
references.pmid: 18555934
references.citation: Jpn J Antibiot. 2005 Dec;58(6):489-506
references.pmid: 16521342
references.citation: J Antimicrob Chemother. 2007 Dec;60(6):1395-7
references.pmid: 17884833
references.citation: Drugs. 1995 Jul;50(1):73-101
references.pmid: 7588092
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1175-87
references.pmid: 15047518
references.citation: Eur Respir J. 2005 Dec;26(6):1138-80
references.pmid: 16319346
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1
references.pmid: 15917558
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2
references.pmid: 18250190
references.citation: Intern Med. 2006;45(7):419-28
references.pmid: 16679695
references.citation: Clin Ther. 2008 Apr;30(4):717-33
references.pmid: 18498921
references.citation: Antimicrob Agents Chemother. 2004 Aug;48(8):3086-92
references.pmid: 15273124
references.citation: J Antimicrob Chemother. 2006 Jul;58(1):37-46
references.pmid: 16757501
references.citation: J Antimicrob Chemother. 2000 Sep;46(3):471-4
references.pmid: 10980177
references.citation: J Chemother. 2002 Apr;14(2):155-60
references.pmid: 12017370
references.citation: J Antimicrob Chemother. 2004 Jul;54(1):144-54
references.pmid: 15190031
references.citation: Jpn J Antibiot. 2007 Dec;60(6):378-86
references.pmid: 18447207
references.citation: Antimicrob Agents Chemother. 2008 Feb;52(2):761-6
references.pmid: 18070958
references.citation: J Clin Microbiol. 2004 Nov;42(11):5256-63
references.pmid: 15528723
references.citation: N Engl J Med. 2008 Mar 20;358(12):1271-81
references.pmid: 18354105
references.citation: Clin Microbiol Infect. 2005 Dec;11(12):974-84
references.pmid: 16307551
references.citation: Antimicrob Agents Chemother. 2006 Feb;50(2):819-21
references.pmid: 16436756
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7
references.pmid: 16127078
references.citation: Microb Drug Resist. 2006 Winter;12(4):223-30
references.pmid: 17227206
references.citation: Expert Opin Pharmacother. 2008 Mar;9(4):561-75
references.pmid: 18312158
references.citation: Drugs. 2004;64(2):159-204
references.pmid: 14717618
references.citation: Chemotherapy. 2004;50 Suppl 1:3-10
references.pmid: 15319548
references.citation: Curr Opin Pharmacol. 2005 Oct;5(5):452-8
references.pmid: 16084766
references.citation: Antimicrob Agents Chemother. 2008 Jan;52(1):365-73
references.pmid: 17938185
references.citation: J Antimicrob Chemother. 1996 May;37(5):1034-6
references.pmid: 8737157
references.citation: Crit Care Med. 2008 Jan;36(1):296-327
references.pmid: 18158437
references.citation: Drugs. 2007;67(3):351-68
references.pmid: 17335295
references.citation: Respir Care. 2004 Dec;49(12):1530-41
references.pmid: 15571647
references.citation: Diagn Microbiol Infect Dis. 2007 Dec;59(4):467-72
references.pmid: 17997070
references.citation: Antimicrob Agents Chemother. 2005 Oct;49(10):4413-7
references.pmid: 16189137
references.citation: J Pharm Sci. 2008 Apr;97(4):1606-14
references.pmid: 17705288
references.citation: Drugs. 2000 Mar;59(3):653-80
references.pmid: 10776838
references.citation: Drugs. 2002;62(15):2221-34; discussion 2235
references.pmid: 12381221
references.citation: J Antimicrob Chemother. 2005 Jun;55(6):944-9
references.pmid: 15872043
references.citation: Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
references.pmid: 17517836
references.citation: Clin Infect Dis. 2005 Nov 15;41(10):1373-406
references.pmid: 16231249
references.citation: Crit Care Clin. 2008 Apr;24(2):261-78, viii
references.pmid: 18361945
references.citation: Drug Metab Rev. 2007;39(4):647-57
references.pmid: 18058328